NCT00935883: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) |
|
|
| Completed | 2 | 60 | US | Eculizumab, Soliris, Saline, PBS | Philip J. Rosenfeld, MD, PhD, Alexion Pharmaceuticals | Age-Related Macular Degeneration | 06/12 | 08/13 | | |